 |
|
|
| |
Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: Day 8 and Week 24 Primary Efficacy and Safety Results (BRIGHTE Study, Formerly 205888/AI438-047)
|
| |
| |
Reported by Jules Levin
EACS - 16th European AIDS Conference, October 25-27, 2017. Milan
M. Kozal1, J. Aberg2, G. Pialoux3, P. Cahn4, M. Thompson5, J.-M. Molina6, B. Grinsztejn7, R. Diaz8, A. Lazzarin9, M. Gummel10, A. Pierce11, P. Ackerman12, C. Llamoso12, M. Lataillade12
1Yale University School of Medicine, New Haven, United States, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3Hopital Tenon, Paris, France, 4Fundación Huesped, Buenos Aires, Argentina, 5AIDS Research Consortium of Atlanta, Atlanta, United States, 6Hôpital Saint Louis, Paris, France, 7Instituto de Pesquisa Clínica Evandro Chagas FIOCRUZ, Rio De Janeiro, Brazil, 8Federal University of São Paulo, São Paulo, Brazil, 9Ospedale San Raffaele, Milan, Italy, 10GlaxoSmithKline, Upper Providence, United States, 11ViiV Healthcare, Research Triangle Park, Branford, United States, 12ViiV Healthcare, Branford, United States
|
| |
|
|
|
|
|
